HORMONE/ FDA APPROVED
Sermorelin
Subcutaneous injection
Overview
A synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid hormone. Sermorelin stimulates the pituitary to produce and release growth hormone through the natural GHRH receptor pathway, preserving the hypothalamic-pituitary feedback axis.
Mechanism of Action
It maintains physiological pulsatile GH secretion patterns.
​Research Summary & Key Findings
FDA-approved for diagnostic evaluation and treatment of growth hormone deficiency in children. Clinical studies demonstrated increases in GH secretion, lean body mass, and improvements in body composition. Shown to improve sleep quality through enhanced slow-wave sleep.
Clinical Status
FDA APPROVED
Sermorelin has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
Subcutaneous injection (weekly)
Administration Routes
METABOLIC
Semaglutide (Ozempic/Wegovy)
METABOLIC
An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds…
METABOLIC
Tirzepatide (Mounjaro/Zepbound)
A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways…
METABOLIC
AOD-9604
A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604…
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.